The National Institutes of Health (NIH) has announced a funding opportunity titled "Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine," aimed at supporting small business technology transfer (STTR) partnerships. This initiative focuses on the development of novel extracellular vesicle (EV)-based therapeutic platforms, addressing challenges related to large-scale manufacturing and production quality, which are critical for tissue and organ repair applications. The funding is essential for advancing therapeutic applications in regenerative medicine, with awards typically not exceeding $295,924 for Phase I and $1,972,828 for Phase II, and proposals must be submitted by June 6, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html.